Dr. Lalji Singh Research Centre, Kalwari Sherwan, Jaunpur, UP, India.

Breast cancer is the most common malignancy in women and leading cause of cancer-related mortality. While significant progress in screening and targeted therapies have improved outcomes in localized disease, but metastatic spread to distant organ remains the major concern.  Each organ site exhibits the unique molecular signatures and microenvironmental condition that shape tumor colonization and resistance. Bone metastasis is driven by a vicious cycle of osteoclast activation and tumor growth. Lung metastasis relies on chemokine signaling, EMT plasticity, and immune evasion. Liver metastasis is supported by metabolic reprogramming and stromal interactions, while brain metastasis is limited by the blood–brain barrier, which restricts effective drug delivery. Current therapeutic strategies involve subtype-specific systemic therapy, but tumor heterogeneity, drug resistance, and organ-specific barriers continue to compromise durable responses. Emerging concepts including liquid biopsy-based surveillance, multi-omics integration, and artificial intelligence driven predictive models ensure earlier detection, personalized interventions, and improved clinical trial design. Future research must aim to transform breast cancer metastasis from an incurable complication into a controllable condition, helping to improve the patient survival and quality of life.